Founder · Longinus Therapeutics
Building the first targeted treatment for 15q11.2 duplication.
I founded Longinus Therapeutics in Madrid after my daughter was diagnosed with a recurrent copy-number variant that has no targeted treatment. We are developing an intrathecal antisense oligonucleotide that lowers CYFIP1 back to wild-type dosage.
At a glance
- Program
- CYFIP1-targeting MOE/DNA gapmer ASO
- Indication
- 15q11.2 BP1-BP2 microduplication
- Stage
- Preclinical · candidate selection
- Based in
- Madrid, Spain